期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

异环磷酰胺联合自体PHA-LAK细胞治疗晚期复发卵巢上皮癌的疗效观察

Ifosfamide with PHA-LAK cell adoptive immunotherapy in advanced recurrent ovarian epithelial cancer
下载PDF
导出
摘要 目的研究异环磷酰胺(ifosfamide,IFO)联合自体PHA-LAK细胞过继性免疫治疗晚期复发卵巢上皮癌的疗效。方法25例复发的晚期卵巢上皮癌患者经IFO1200mg/(m2·d)连用4d,同时于用IFO后0、4、8h分别静脉推注美司钠400mg;化疗间歇期以PHA-LAK细胞治疗4次。联合治疗2个周期以上。结果25例患者中,完全缓解(CR)3例,部分缓解(PR)8例,稳定(NC)7例,进展(PD)7例,有效率(CR+PR)44%(11/25),中位无进展生存期(TTP)21周,中位生存期(OS)47周。毒副反应主要是消化道反应和骨髓抑制。结论IFO联合自体PHA-LAK细胞治疗复发的晚期卵巢上皮癌有效,毒副反应低,可作为晚期复发卵巢上皮癌的选择方案。 OBJECTIVE： To investigate the efficacy and safety of ifosfamide with PHA-LAK cell adoptive immunotherapy in advanced recurrent ovarian epithelial cancer. METHODS： IFO was administered in the dosage of t 200 mg/m^2 on days 1- 4 with mesna （400 mg） infusion at 0,4 and 8 hours following initiation of IFO. The PHA-LAK cells were given intravenously 4 times during the intermission of chemotherapy. This regimen was repeated at least 2 cycles. RESULTS： There were 3/25-CR, 8/ 25 PR, 7/25 NC, 7/25-PD. CR ＋ PR 44 %. Median TTP and OS were 21 weeks and 47 weeks respectively. CONCLUSIONS： The therapy of IFO with PHA-LAK cells has efficacy in women with advanced recurrent ovarian epithelial cancer. Its toxicity is slight and so the protocol can be a reasonable option in the treatment of advanced recurrent ovarian cancer.
作者 黄媚娟 姜愚 周麟 李梅 彭枫
机构地区 四川大学华西医院肿瘤中心生物治疗科
出处 《肿瘤防治杂志》 CAS 2005年第13期1015-1017,共3页 China Journal of Cancer Prevention and Treatment
关键词 卵巢肿瘤/药物疗法 卵巢肿瘤免疫疗法 异环磷酰胺 杀伤细胞 淋巴因子激活/药理学 ovarian neoplasms/drug therapy ovarian neoplasms/immunotherapy ifosfamide （IFO） killer cells,lymphokine-activated/pharmacology
分类号 R737.31 [医药卫生—肿瘤]
  • 相关文献

参考文献18

  • 1孙燕 周际昌.临床肿瘤内科手册[M].北京：人民卫生出版社,2003.586-591.
  • 2Christian M C, Trimble E L. Salvage chemotherapy for epithelial ovarian carcinoma[J].Gynecol Oncol, 1994, 55(3 Pt 2):S143-150.
  • 3Armstrong D K. Relapsed ovarian cancer: challenges and management strategies for a chronic disease [J]. The Oncologist,2002,7(5):20-28.
  • 4McGuire W P, Blessing J A, Bookman M A, et al. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group study [J]. J Clin Oncol, 2000, 18(5):1062-1067.
  • 5Eisenhauer E A, Vermorken J B, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients [J]. Ann Oncol ,1997,8(10):963-968.
  • 6Shaheen M, Stender M J, McClean J W, et al. Phase II study of ifosfamide plus daily oral etoposide in previously treated ovarian cancer: a Hoosier Oncology Group (HOG) study [J]. Am J Clin Oncol, 2004, 27(3):229-231.
  • 7Dorval T, Soussain C, Beuzeboc P, et al. Ifosfamide seven-day infusion for recurrent and cisplatin refractory ovarian cancer[J]. J Infus Chemother, 1996,6(1):47-49.
  • 8Nardi M, De Marco S, Fabi A, et al. Ifosfamide and vinorelbine in advanced pretreated ovarian cancer: a phase Ⅱ study[J].Cancer Chemother Pharmacol,2000,45(6):513-515.
  • 9Lissoni A A, Fei F, Rossi R, et al.Ifosfamide in the treatment of malignant epithelial ovarian tumors[J]. Oncology,2003, 65(Suppl 2):59-62.
  • 10Charles J L, Tatinia S, Ann T, et al. Cellular suicide therapy of malignant disease[J]. Stem Cells, 2000,18(3):220-226.

二级参考文献13

  • 1Gritzapis AD, Dimitroulopoulos D, Paraskevas E, et al. Large-scale expansion of CD3(+)CD56(+) lymphocytes capable of lysing autologous tumor cells with cytokine-rich supernatants[J] . Cancer Immunol Immunother, 2002 ,51(8):440-448.
  • 2Yamauchi A, Taga K, Mostowski HS, et al. Target cell-induced apoptosis of interleukin-2-activated human natural killer cells: roles of cell surface molecules and intracellular events[J]. Blood, 1996 ,87(12):5127-5135.
  • 3Matsuda M, Petersson M, Lenke R. Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease[J] . Int J Cancer, 1995,61(6): 765
  • 4Houghton A.N. Cancer antigens:Immune recognition of self and altered self[J] .J Exp Med,1994,801(1):1-4.
  • 5Valteau-Couanet D, Leboulaire C, Maincent K, et al. Dendritic cells for NK/LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients[J]. Blood, 2002 ,100(7):2554-2561.
  • 6Rosenberg SA. Progress in human tumour immunology and immunotherapy[J]. Nature. 2001, 411(6835):380-384.
  • 7Valteau-Couanet D, Leboulaire C, Maincent K, et al. Dendritic cells for NK/LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients[J]. Blood. 2002 ,100(7):2554-2261.
  • 8Morse MA, Clay TM, Lyerly HK. et al. Current status of adoptive immunotherapy of malignancies[J]. Expert Opin Biol Ther, 2002,2(3):237-247.
  • 9Pardoll DM. Inducing autoimmune disease to treat cancer[J]. Proc Natl Acad Sic USA, 1999, 969(10):5340-5342.
  • 10Reichert T E, Rabinowich H, Johnson J T.et al. Human immune cells in the tumor microenvironment: mechanism responsible for signaling and functional defects[J]. J Immunother, 1998,21(4): 295-306.

共引文献387

肿瘤防治杂志
2005年 第13期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部